Gregory B. Lesinski, PhD, MPH

Research Program

Cancer Immunology
Email Address

gregory.b.lesinski@emory.edu

Biography

Gregory B. Lesinski, PhD, MPH, is professor and serves as vice chair for basic research in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Lesinski also serves as Winship Cancer Institute's associate director for basic research and shared resources where he provides oversight and direction for the development and growth of Winship's basic scientific activities across the cancer center’s four research programs. Prior to joining Emory, Dr. Lesinski was associate professor in the Department of Internal Medicine, Division of Medical Oncology at The Ohio State University.

Education

Dr. Lesinski received his PhD in Biomedical Sciences from The Medical College of Ohio in Toledo, Ohio. He obtained his MPH in Clinical Investigation from The Ohio State University in Columbus, Ohio. He completed his post-doctoral training at The Ohio State University.

Titles & Roles

John Kauffman Family Professorship for Pancreatic Cancer Research

Emory University School of Medicine
Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Associate Director for Basic Research and Shared Resources

Winship Cancer Institute of Emory University
Co-Director Translational GI Malignancy Program

Winship Cancer Institute of Emory University
Vice Chair for Basic Research, Department of Hematology and Medical Oncology

Emory University School of Medicine

Professional Memberships

American Association for Cancer Research
Society for Melanoma Research
Society for Immunotherapy of Cancer
American Association of Immunologists

Research

Dr. Lesinski's research is focused on gaining a greater understanding of the interactions between the host immune system and tumor cells. The ultimate goal is to use this knowledge to develop novel therapeutic or chemo-preventative approaches to help patients with cancer, and improve upon existing therapies. Of particular interest are modulation of cytokines and downstream signaling pathways to maximize the effect of immune based therapy.

Grants

View Grants

Grant Number	Title
1R21CA270903-01A1	Preoperative immunotherapy in Hepatocellular Carcinoma
1T32CA272392-01A1	Graduate Program in Cancer Biology Training at Emory University
5R01CA228406-05	Targeting immune stroma interactions in pancreatic cancer
5R21CA270903-02	Preoperative immunotherapy in Hepatocellular Carcinoma
5T32CA272392-02	Graduate Program in Cancer Biology Training at Emory University

Publications

Dr. Lesinski has published numerous articles in peer-reviewed journals including Journal of Immunology, Journal of the National Cancer Institute, and Journal of Clinical Investigation.

Title/Journal	Authors	Publication Date
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial. Oncoimmunology	MJ Phillips, OB Alese, NK Horvat, E Greene, OB Gbolahan, K Coleman, DB Doxie, V Parihar, ZK Mahdi, A McCook-Veal, JM Switchenko, M Diab, CJ Herting, CM Paulos, BF El-Rayes, GB Lesinski	12/01/2025
Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node. Nature communications	Y Shen, E Connolly, M Aiello, C Zhou, P Chappa, H Song, P Tippitak, T Clark, M Cardenas, N Prokhnevska, A Mariniello, I De Bruyker, MS Pagadala, VR Dhere, S Rafiq, AH Kesarwala, A Orthwein, SN Thomas, SL Zhang, MK Khan, JB Dixon, GB Lesinski, MC Lowe, H Kissick, DS Yu, CM Paulos, NC Schmitt, ZS Buchwald	04/14/2025
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Cell reports. Medicine	GP Nagaraju, MS Saddala, JB Foote, AM Khaliq, A Masood, Y Golivi, DSR Bandi, S Sarvesh, SP Reddy, J Switchenko, JL Carstens, M Akce, C Herting, OB Alese, KJ Yoon, U Manne, MK Bhasin, GB Lesinski, VP Sukhatme, BF El-Rayes	01/21/2025
Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer. Molecular therapy. Oncology	HK Lin, DA Blake, T Liu, R Freeman, GB Lesinski, L Yang, S Rafiq	12/19/2024
A pilot study of the immune microenvironment of GI neuroendocrine carcinoma. Endocrine-related cancer	A McDonald, V Avadhani, G Oprea-Ilies, K Zakka, GB Lesinski, OB Gbolahan, O Alese	10/01/2024
VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer. Cancer research	T Passang, S Wang, H Zhang, F Zeng, PC Hsu, W Wang, JM Li, Y Liu, S Ravindranathan, GB Lesinski, EK Waller	09/16/2024
Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells. Journal for immunotherapy of cancer	MC Wittling, HM Knochelmann, MM Wyatt, GO Rangel Rivera, AC Cole, GB Lesinski, CM Paulos	06/30/2024
Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer. Journal of experimental & clinical cancer research : CR	F Yang, C Yuan, F Chen, ZS Qin, NC Schmitt, GB Lesinski, NF Saba, Y Teng	03/12/2024
Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node. Research square	Y Shen, E Connolly, M Aiello, C Zhou, P Chappa, H Song, P Tippitak, T Clark, M Cardenas, N Prokhnevska, A Mariniello, MS Pagadala, VR Dhere, S Rafiq, AH Kesarwala, A Orthwein, SN Thomas, MK Khan, J Brandon Dixon, GB Lesinski, MC Lowe, H Kissick, DS Yu, CM Paulos, NC Schmitt, ZS Buchwald	03/06/2024
Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. Journal for immunotherapy of cancer	NK Horvat, I Karpovsky, M Phillips, MM Wyatt, MA Hall, CJ Herting, J Hammons, Z Mahdi, RA Moffitt, CM Paulos, GB Lesinski	01/08/2024
Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3Kδ Blockade Improves Metabolism and Antitumor Immunity. Cancer research	GO Rangel Rivera, CJ Dwyer, HM Knochelmann, AS Smith, BA Aksoy, AC Cole, MM Wyatt, S Kumaresan, JE Thaxton, GB Lesinski, CM Paulos	01/02/2024
Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells. bioRxiv : the preprint server for biology	MC Wittling, HM Knochelmann, MM Wyatt, GO Rangel Rivera, AC Cole, GB Lesinski, CM Paulos	12/18/2023
Top advances of the year: Pancreatic cancer. Cancer	EAK Warren, GB Lesinski, SK Maithel	12/15/2023
Trans-vaccenic acid reprograms CD8⁺ T cells and anti-tumour immunity. Nature	H Fan, S Xia, J Xiang, Y Li, MO Ross, SA Lim, F Yang, J Tu, L Xie, U Dougherty, FQ Zhang, Z Zheng, R Zhang, R Wu, L Dong, R Su, X Chen, T Althaus, PA Riedell, PB Jonker, A Muir, GB Lesinski, S Rafiq, MV Dhodapkar, W Stock, O Odenike, AA Patel, J Opferman, T Tsuji, J Matsuzaki, H Shah, B Faubert, SE Elf, B Layden, BM Bissonnette, YY He, J Kline, H Mao, K Odunsi, X Gao, H Chi, C He, J Chen	11/01/2023
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer. Journal for immunotherapy of cancer	M Akce, B Farran, JM Switchenko, M Rupji, S Kang, L Khalil, A Ruggieri-Joyce, B Olson, WL Shaib, C Wu, OB Alese, M Diab, GB Lesinski, BF El-Rayes	10/01/2023
Impact of nodal status in determining multimodal treatment strategies in non-cardia gastric cancer. Journal of surgical oncology	PS Ajay, CP Sok, S Goyal, JM Switchenko, FB Maegawa, TW Gillespie, CM Paulos, GB Lesinski, DA Kooby, TJ Kennedy, MM Shah	08/01/2023
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022). Journal of translational medicine	PA Ascierto, A Avallone, C Bifulco, S Bracarda, JD Brody, LA Emens, RL Ferris, SC Formenti, O Hamid, DB Johnson, T Kirchhoff, CA Klebanoff, GB Lesinski, A Monette, B Neyns, K Odunsi, CM Paulos, DJ Powell, K Rezvani, BH Segal, N Singh, RJ Sullivan, BA Fox, I Puzanov	07/20/2023
Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells. Molecular therapy : the journal of the American Society of Gene Therapy	MM Wyatt, LW Huff, MH Nelson, LR Neal, AR Medvec, GO Rangel Rivera, AS Smith, AM Rivera Reyes, HM Knochelmann, JL Riley, GB Lesinski, CM Paulos	07/05/2023
Short-Term Soy Bread Intervention Leads to a Dose-Response Increase in Urinary Isoflavone Metabolites and Satiety in Chronic Pancreatitis. Foods (Basel, Switzerland)	JH Ahn-Jarvis, D Sosh, E Lombardo, GB Lesinski, DL Conwell, PA Hart, Y Vodovotz	04/24/2023
Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner. JCI insight	MB Ware, M Phillips, C McQuinn, MY Zaidi, HM Knochelmann, E Greene, B Robinson, CJ Herting, TA Mace, Z Chen, C Zhang, MR Farren, AN Ruggieri, JS Bowers, R Shakya, AB Farris, G Young, WE Carson, B El-Rayes, CM Paulos, GB Lesinski	04/24/2023
The degree of T cell stemness differentially impacts the potency of adoptive cancer immunotherapy in a Lef-1 and Tcf-1 dependent manner. bioRxiv : the preprint server for biology	GO Rangel Rivera, CJ Dwyer, HM Knochelmann, AS Smith, A Aksoy, AC Cole, MM Wyatt, JE Thaxton, GB Lesinski, CM Paulos	03/10/2023
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. Journal for immunotherapy of cancer	V Kansal, AJ Burnham, BLC Kinney, NF Saba, C Paulos, GB Lesinski, ZS Buchwald, NC Schmitt	01/01/2023
The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]	S Han, DL Conwell, L Li, A Cervantes, PA Hart, Z Cruz-Monserrate, W Hao, GB Lesinski, T Mace, TM Palermo, JL Saloman, D Yadav, SS Vege, M Topazian	01/01/2023
Bring on the brequinar: an approach to enforce the differentiation of myeloid-derived suppressor cells. The Journal of clinical investigation	NK Horvat, GB Lesinski	12/01/2022
STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Life science alliance	JE Lefler, CB MarElia-Bennett, KA Thies, BE Hildreth, SM Sharma, JR Pitarresi, L Han, C Everett, C Koivisto, MC Cuitino, CD Timmers, E O'Quinn, M Parrish, MJ Romeo, AJ Linke, GA Hobbs, G Leone, DC Guttridge, TA Zimmers, GB Lesinski, MC Ostrowski	11/01/2022
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Nature communications	S Ravindranathan, T Passang, JM Li, S Wang, R Dhamsania, MB Ware, MY Zaidi, J Zhu, M Cardenas, Y Liu, S Gumber, B Robinson, A Sen-Majumdar, H Zhang, S Chandrakasan, H Kissick, AB Frey, SN Thomas, BF El-Rayes, GB Lesinski, EK Waller	10/27/2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	AN Ruggieri, M Yarchoan, S Goyal, Y Liu, E Sharon, HX Chen, BM Olson, CM Paulos, BF El-Rayes, SK Maithel, NS Azad, GB Lesinski	10/03/2022
GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut	LI Ruffolo, KM Jackson, PC Kuhlers, BS Dale, NM Figueroa Guilliani, NA Ullman, PR Burchard, SS Qin, PG Juviler, JM Keilson, AB Morrison, M Georger, R Jewell, LM Calvi, TM Nywening, MR O'Dell, AF Hezel, L De Las Casas, GB Lesinski, JJ Yeh, R Hernandez-Alejandro, BA Belt, DC Linehan	07/01/2022
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO precision oncology	K Mody, P Jain, SM El-Refai, NS Azad, DJ Zabransky, M Baretti, RT Shroff, RK Kelley, AB El-Khouiery, AJ Hockenberry, D Lau, GB Lesinski, M Yarchoan	06/01/2022
Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model. Virology journal	S Tang, L Shi, BT Luker, C Mickler, B Suresh, GB Lesinski, D Fan, Y Liu, M Luo	02/23/2022
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. The Journal of clinical investigation	M Yarchoan, L Cope, AN Ruggieri, RA Anders, AM Noonan, LW Goff, L Goyal, J Lacy, D Li, AK Patel, AR He, GK Abou-Alfa, K Spencer, EJ Kim, SL Davis, AJ McRee, PR Kunk, S Goyal, Y Liu, L Dennison, S Xavier, AA Mohan, Q Zhu, A Wang-Gillam, A Poklepovic, HX Chen, E Sharon, GB Lesinski, NS Azad	12/15/2021
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer immunology, immunotherapy : CII	CJ Herting, MR Farren, Y Tong, Z Liu, B O'Neil, T Bekaii-Saab, A Noonan, C McQuinn, TA Mace, W Shaib, C Wu, BF El-Rayes, S Shahda, GB Lesinski	11/01/2021
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy. Cancer immunology research	L Dennison, A Ruggieri, A Mohan, J Leatherman, K Cruz, S Woolman, N Azad, GB Lesinski, EM Jaffee, M Yarchoan	10/01/2021
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Cancer metastasis reviews	CJ Herting, I Karpovsky, GB Lesinski	09/01/2021
Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer. Annals of surgical oncology	AJ Rossi, TM Khan, H Hong, GB Lesinski, C Wu, JM Hernandez	08/01/2021
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. The oncologist	IH Sahin, S Goyal, Y Pumpalova, MB Sonbol, S Das, S Haraldsdottir, D Ahn, KK Ciombor, Z Chen, A Draper, J Berlin, T Bekaii-Saab, GB Lesinski, BF El-Rayes, C Wu	08/01/2021
Braking the cell's cycle and invigorating T-cell immunity against pancreatic cancer. Gut	GB Lesinski	01/01/2021
Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Molecular cancer therapeutics	Y Zhang, MB Ware, MY Zaidi, AN Ruggieri, BM Olson, H Komar, MR Farren, GP Nagaraju, C Zhang, Z Chen, JM Sarmiento, R Ahmed, SK Maithel, BF El-Rayes, GB Lesinski	01/01/2021
Delayed Processing of Secretin-Induced Pancreas Fluid Influences the Quality and Integrity of Proteins and Nucleic Acids. Pancreas	Z Cruz-Monserrate, K Gumpper, S Kaul, N Badi, S Terhorst, K Dubay, GB Lesinski, W Fisher, A McElhany, LF Lara, S Krishna, T Mace, N Higuita-Castro, L Ortega-Pineda, MA Freitas, A Hinton, D Yadav, PA Hart, SJ Pandol, S Ahmed, B Fatou, H Steen, DL Conwell	01/01/2021
Lymph Node Subcapsular Sinus Microenvironment-On-A-Chip Modeling Shear Flow Relevant to Lymphatic Metastasis and Immune Cell Homing. iScience	KG Birmingham, MJ O'Melia, S Bordy, D Reyes Aguilar, B El-Reyas, G Lesinski, SN Thomas	11/20/2020
Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. British journal of cancer	MB Ware, MY Zaidi, J Yang, MK Turgeon, A Krasinskas, TA Mace, K Keenan, MR Farren, AN Ruggieri, Y Li, C Zhang, Z Chen, GS Young, O Elnaggar, Z Che, SK Maithel, T Bekaii-Saab, B El-Rayes, GB Lesinski	10/01/2020
IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors. Cancer research	HM Knochelmann, CJ Dwyer, AS Smith, JS Bowers, MM Wyatt, MH Nelson, GO Rangel Rivera, JD Horton, C Krieg, K Armeson, GB Lesinski, MP Rubinstein, Z Li, CM Paulos	09/15/2020
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. Journal for immunotherapy of cancer	MB Ware, BF El-Rayes, GB Lesinski	08/01/2020
Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer. Cancer	GP Nagaraju, B Farran, M Farren, G Chalikonda, C Wu, GB Lesinski, BF El-Rayes	07/15/2020
Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency. Biomacromolecules	LA Perdue, P Do, C David, A Chyong, AV Kellner, A Ruggieri, HR Kim, K Salaita, GB Lesinski, CC Porter, EC Dreaden	07/13/2020
Reduction of inflammation in chronic pancreatitis using a soy bread intervention: A feasibility study. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]	J Ahn-Jarvis, E Lombardo, Z Cruz-Monserrate, N Badi, O Crowe, S Kaul, H Komar, SG Krishna, GB Lesinski, TA Mace, ML Ramsey, K Roberts, K Stinehart, M Traczek, DL Conwell, Y Vodovotz, PA Hart	07/01/2020
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. JCO oncology practice	IH Sahin, SR Kane, E Brutcher, J Guadagno, KE Smith, C Wu, GB Lesinski, CJ Gunthel, BF El-Rayes	06/01/2020
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI insight	MR Farren, L Sayegh, MB Ware, HR Chen, J Gong, Y Liang, A Krasinskas, SK Maithel, M Zaidi, JM Sarmiento, D Kooby, P Patel, B El-Rayes, W Shaib, GB Lesinski	01/16/2020
Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. Molecular cancer research : MCR	S Chandrasekaran, M Sasaki, CD Scharer, HT Kissick, DG Patterson, KR Magliocca, JT Seykora, B Sapkota, DA Gutman, LA Cooper, GB Lesinski, EK Waller, SN Thomas, SV Kotenko, JM Boss, CS Moreno, RA Swerlick, BP Pollack	12/01/2019
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. British journal of cancer	IH Sahin, M Akce, O Alese, W Shaib, GB Lesinski, B El-Rayes, C Wu	11/01/2019
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. International journal of cancer	GP Nagaraju, KM Zakka, JC Landry, WL Shaib, GB Lesinski, BF El-Rayes	09/15/2019
Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma. Head and neck pathology	GB Lesinski, S Nannapaneni, CC Griffith, M Patel, W Chen, Z Chen, R Ahmed, A Wieland, DM Shin, ZG Chen, NF Saba	09/01/2019
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation. Oncogene	L Deng, G Qian, S Zhang, H Zheng, S Fan, GB Lesinski, TK Owonikoko, SS Ramalingam, SY Sun	08/01/2019
Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function. Scientific reports	TA Mace, MB Ware, SA King, S Loftus, MR Farren, E McMichael, S Scoville, C Geraghty, G Young, WE Carson, SK Clinton, GB Lesinski	03/25/2019
Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]	ML Ramsey, E Talbert, D Ahn, T Bekaii-Saab, N Badi, PM Bloomston, DL Conwell, Z Cruz-Monserrate, M Dillhoff, MR Farren, A Hinton, SG Krishna, GB Lesinski, T Mace, A Manilchuk, A Noonan, TM Pawlik, PV Rajasekera, C Schmidt, D Guttridge, PA Hart	01/01/2019
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. PloS one	M Yarchoan, AA Mohan, L Dennison, T Vithayathil, A Ruggieri, GB Lesinski, TD Armstrong, NS Azad, EM Jaffee	01/01/2019
Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells. Annals of pancreatic cancer	GB Lesinski	10/01/2018
Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. Life science alliance	JR Pitarresi, X Liu, A Avendano, KA Thies, GM Sizemore, AM Hammer, BE Hildreth, DJ Wang, SA Steck, S Donohue, MC Cuitiño, RD Kladney, TA Mace, JJ Chang, CS Ennis, H Li, RH Reeves, S Blackshaw, J Zhang, L Yu, SA Fernandez, WL Frankel, M Bloomston, TJ Rosol, GB Lesinski, SF Konieczny, DC Guttridge, AK Rustgi, G Leone, JW Song, J Wu, MC Ostrowski	10/01/2018
Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. Journal of cachexia, sarcopenia and muscle	EE Talbert, HL Lewis, MR Farren, ML Ramsey, JM Chakedis, P Rajasekera, E Haverick, A Sarna, M Bloomston, TM Pawlik, TA Zimmers, GB Lesinski, PA Hart, ME Dillhoff, CR Schmidt, DC Guttridge	04/01/2018
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut	TA Mace, R Shakya, JR Pitarresi, B Swanson, CW McQuinn, S Loftus, E Nordquist, Z Cruz-Monserrate, L Yu, G Young, X Zhong, TA Zimmers, MC Ostrowski, T Ludwig, M Bloomston, T Bekaii-Saab, GB Lesinski	02/01/2018
The Potential of CAR T Cell Therapy in Pancreatic Cancer. Frontiers in immunology	M Akce, MY Zaidi, EK Waller, BF El-Rayes, GB Lesinski	01/01/2018
Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. Journal of clinical pharmacology	AE Kersh, S Ng, YM Chang, M Sasaki, SN Thomas, HT Kissick, GB Lesinski, RR Kudchadkar, EK Waller, BP Pollack	01/01/2018
Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas	WE Fisher, Z Cruz-Monserrate, AL McElhany, GB Lesinski, PA Hart, R Ghosh, G Van Buren, DS Fishman, JAS Rinaudo, J Serrano, S Srivastava, T Mace, M Topazian, Z Feng, D Yadav, SJ Pandol, SJ Hughes, RY Liu, E Lu, R Orr, DC Whitcomb, AS Abouhamze, H Steen, ZM Sellers, DM Troendle, A Uc, ME Lowe, DL Conwell	01/01/2018
Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. Cancer	A Belalcazar, WL Shaib, MR Farren, C Zhang, Z Chen, L Yang, GB Lesinski, BF El-Rayes, GP Nagaraju	12/15/2017
Local and Systemic Expression of Immunomodulatory Factors in Chronic Pancreatitis. Pancreas	HM Komar, PA Hart, Z Cruz-Monserrate, DL Conwell, GB Lesinski	09/01/2017
Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. Cancer letters	GP Nagaraju, C Wu, N Merchant, Z Chen, GB Lesinski, BF El-Rayes	08/28/2017
Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Cancer research	SB Gomez-Chou, AK Swidnicka-Siergiejko, N Badi, M Chavez-Tomar, GB Lesinski, T Bekaii-Saab, MR Farren, TA Mace, C Schmidt, Y Liu, D Deng, RF Hwang, L Zhou, T Moore, D Chatterjee, H Wang, X Leng, RB Arlinghaus, CD Logsdon, Z Cruz-Monserrate	05/15/2017
Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Scientific reports	HM Komar, G Serpa, C Kerscher, E Schwoegl, TA Mace, M Jin, MC Yang, CS Chen, M Bloomston, MC Ostrowski, PA Hart, DL Conwell, GB Lesinski	05/11/2017
Mathematical model of chronic pancreatitis. Proceedings of the National Academy of Sciences of the United States of America	W Hao, HM Komar, PA Hart, DL Conwell, GB Lesinski, A Friedman	05/09/2017
Signaling pathways as therapeutic targets in biliary tract cancer. Expert opinion on therapeutic targets	J Yang, MR Farren, D Ahn, T Bekaii-Saab, GB Lesinski	05/01/2017
Laser Capture Microdissection of Pancreatic Acinar Cells to Identify Proteomic Alterations in a Murine Model of Caerulein-Induced Pancreatitis. Clinical and translational gastroenterology	JP Shapiro, HM Komar, B Hancioglu, L Yu, M Jin, Y Ogata, PA Hart, Z Cruz-Monserrate, GB Lesinski, DL Conwell	04/13/2017
The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Molecular cancer therapeutics	MR Farren, RC Hennessey, R Shakya, O Elnaggar, G Young, K Kendra, Y Landesman, S Elloul, M Crochiere, B Klebanov, T Kashyap, CE Burd, GB Lesinski	03/01/2017
Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Molecular cancer therapeutics	EE Talbert, J Yang, TA Mace, MR Farren, AB Farris, GS Young, O Elnaggar, Z Che, CD Timmers, P Rajasekera, JM Maskarinec, M Bloomston, T Bekaii-Saab, DC Guttridge, GB Lesinski	02/01/2017
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas. Cancer immunology, immunotherapy : CII	MC Duggan, C Jochems, RN Donahue, J Richards, V Karpa, E Foust, B Paul, T Brooks, S Tridandapani, T Olencki, X Pan, GB Lesinski, J Schlom, WE Carson Iii	11/01/2016